The Serum Institute of India's recombinant Bacillus Calmette-Guerin (BCG) vaccine would be the first vaccine candidate in India to start human trials within the next two weeks, reported Business Standard.
The trials will test if the BCG vaccine, administered at birth to Indians to fight tuberculosis, can also boost immunity in adults against the novel coronavirus.
CEO Adar Poonawalla said "this is an extremely safe vaccine, since it is given to newborn babies, and [it has been available] in more than 100 countries worldwide for more than two decades."
The executive added "there is a demand for this vaccine, and we can make 300 million to 400 million doses…but until the trials are over, we are not officially prescribing it."
To read more NewsPoints articles, click here.